Overview

Hepatic Metabolic Changes in Response to Glucagon Infusion

Status:
Completed
Trial end date:
2019-06-12
Target enrollment:
0
Participant gender:
All
Summary
The objective of the study is to investigate how exogenously administered glucagon affects hepatic lipid, glucose and protein metabolism as well as appetite, food intake and resting energy expenditure.
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Steno Diabetes Center
Steno Diabetes Center Copenhagen
Collaborator:
University of Copenhagen
Treatments:
Glucagon
Glucagon-Like Peptide 1
Criteria
Inclusion Criteria:

Pancreatectomised patients

- Patients who have undergone total pancreatectomy

- Caucasian between 30-80

- Blood haemoglobin >7.0 mmol/l for males and >6.5 mmol/l for females

- Informed consent

Patients with type 1 diabetes

- Patients with C-peptide negative type 1 diabetes

- Caucasian between 30-80

- Blood haemoglobin >7.0 mmol/l for males and >6.5 mmol/l for females

- Informed consent

Healthy controls

- Normal fasting plasma glucose (< 7 mmol/l) and normal HbA1c (< 6.5 %) (30,31)

- Normal blood haemoglobin (>8.3 mmol/l for males and >7.3 mmol/l for females)

- Caucasian between 30-80

- Informed consent

Exclusion Criteria:

All subjects

- Inflammatory bowel disease

- Gastrointestinal resection (other than the gastro-duodenectomy performed in connection
with total pancreatectomy) and/or ostomy

- Nephropathy (eGFR < 60 ml/min/1.73 m² and/or urine albumin > 20 mg/L)

- Known liver disease (excluding non-alcoholic fatty liver disease)

- Severe lung disease

- Pregnancy and/or breastfeeding

- Uncontrolled hypertension and/or significant cardiovascular disease

- Treatment with drugs with potential steatogenic side-effects within three months prior
to inclusion

- Alcohol consumption above 21 units/week for men and 14 units/week for women

- Any condition that the investigator feels would interfere with the safety of the trial
participation or the safety of the subject.